Iopamidol

Iopamidol

Clinical data
Trade names	Isovue, Iopamiro, Gastromiro, others
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of administration	Intravascular, intravenous, intrathecal
ATC code	V08AB04 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: WARNINGRx-only
Identifiers
IUPAC name 1-N,3-N-bis(1,3-dihydroxypropan-2-yl)-5-[(2S)-2-hydroxypropanamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
CAS Number	60166-93-0 N
PubChem CID	65492
DrugBank	DB08947 N
ChemSpider	58940
UNII	JR13W81H44
KEGG	D01797 Y
ChEBI	CHEBI:31711 N
ChEMBL	ChEMBL1200932 N
CompTox Dashboard (EPA)	DTXSID1023158
ECHA InfoCard	100.056.430
Chemical and physical data
Formula	C17H22I3N3O8
Molar mass	777.089 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H](C(=O)Nc1c(c(c(c(c1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)O
InChI InChI=1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1 Key:XQZXYNRDCRIARQ-LURJTMIESA-N
NY (what is this?)  (verify)

Iopamidol (INN), sold under the brand name Isovue among others, is a nonionic, low-osmolar iodinated contrast agent, developed by Bracco Diagnostics.

It is available in various concentrations, from 200 to 370 mgI/mL.

Medical uses

Iopamidol is indicated for angiography throughout the cardiovascular system, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography (phlebography), and adult and pediatric intravenous excretory urography and intravenous adult and pediatric contrast enhancement of computed tomographic (CECT) head and body imaging.

It is also indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography. Isovue-M 200 (lopamidol Injection) is indicated for thoraco-lumbar myelography in children over the age of two years.

As with other iodinated contrast agents there are concerns regarding safety, particularly relating to effects on renal function and allergic type reaction. Early generations of intravenous (IV) contrast carried considerable nephrotoxicity, necessitating continual assessment of renal function. IV and PO (per os, by mouth) fluids are encouraged post operation to facilitate excretion of contrast. Shellfish allergies have previously thought to have crossover with iodine allergies with caution being advised with regards to the use of iodinated contrast in patients with shellfish, however shellfish have been demonstrated to be due to proteins produced by the organisms, not due to iodine.